Dr. Saif Shere
Dr. Saif Shere of Brownstone Dental

HOUSTON, January 27, 2023 (Newswire.com) - Houstonians love their celebrities. But what if they could get the same treatment a celebrity gets when they visit the dentist? Brownstone Dental, founded by Dr. Saif Shere, is now offering the latest in dental technology and care to its patients with a new way to treat both general and cosmetic dental needs.

"We are so excited to offer this new opportunity for our patients," said Dr. Shere. "I really believe that everyone deserves a chance to feel like they're getting VIP treatment when they go to the dentist."

Known for his expertise, Dr. Saif Shere graduated with honors and became a board-certified dentist in 2008. Later, in 2010, he founded his own practice - Brownstone Dental. After more than a decade of service, Dr. Saif Shere has earned the reputation of being Houston's premier dental practitioner.

Many prominent personalities, including rappers and athletes, have had their teeth worked on by Dr. Shere. His patients come from all over the world because they know they can trust him to do the best work possible. Dr. Shere understands that people have different needs when it comes to their teeth, and he makes sure to take those needs into account at every appointment.

Dr. Shere is famous for treating his patients with a level of care that goes above and beyond what most dentists provide, but what sets him apart is his approach to cosmetic dentistry, which is all about innovation. 

"I want to give them the Bollywood smile," says Dr. Shere. 

In an industry where most dentists are content with the same old procedures, he always looks for new ways to improve the smile of their patients. From advanced technology that allows him to offer the latest in dental techniques to the innovative use of customized methods, Dr. Shere has embraced the future of dentistry and uses it every day to help his patients get the perfect smile.

He went to Klein High School before attending the University of Houston and then Baylor College of Dentistry. If Dr. Shere wasn't a celebrity dentist today, he would likely be teaching history at an esteemed university somewhere around town.

Shere's first celebrity case was four years ago when he worked with a prominent rapper. In his own words, "Every patient is a celebrity to me! We treat all of our patients with extravagant care."

Dr. Shere believes that when it comes to getting the best, there's always room for improvement. With this in mind, he and his team have been working on new ways to help patients achieve their dream smile—one that offers more options than ever before.

For dental work that needs to be done soon, scheduling an appointment with Dr. Shere is possible at Brownstone Dental. They can be contacted at (713) 271-3000 or visited at 9824 Fondren Rd., Houston, TX 77096, United States.

TORONTO, January 26, 2023 (Newswire.com) - Smile CDR Inc. (doing business as Smile Digital Health) ("Smile"), a leading FHIR® health data fabric (HDF) and exchange solutions provider, announced the closing of approximately $30 million in Series B growth capital led by existing investors including UPMC Enterprises. 

Smile's HDF platform uses industry-leading HDF architecture and ONC-compliant, event-driven FHIR APIs to allow healthcare providers, payers and IT vendors to build secure, composable and scalable data infrastructures. Smile offers a suite of health data, clinical reasoning and marketplace utilities that can support ecosystem-wide data innovation and digital modernization efforts to accelerate healthcare innovation, improve quality of patient care journeys, boost operational efficiencies and reduce costs using intelligent automation implementation strategies.

"Our vision for better global health becomes more achievable when we focus on the inherent value of finding innovative ways to efficiently share and use data. Smile Digital Health has seen significant growth in our platform because it does just this. With transformative solutions that can meet companies' specific needs, we are preparing healthcare providers, payers, researchers and life sciences organizations for a connected future that transcends the capabilities of today's systems," said Duncan Weatherston, Chief Executive Officer at Smile Digital Health. 

Smile Digital Health is committed to continuing its advancements in end-to-end interoperability with expanded offerings that enhance the breadth of its data fabric solutions for future digital transformations. The company will use this new round of funding to expand its newly acquired clinical reasoning utility and forward-looking artificial intelligence and machine learning capabilities, further advancing Smile Digital Health as the leader in the field.

"Data fabrics open up many new ways of leveraging and working with health data. We will continue to delve into creating solutions that drive change in healthcare and enable better outcomes for everyone. We will also optimize our solutions, as new regulations and mandates are passed, consistently maintaining offerings that keep payers and providers compliant. When new innovations emerge in the industry, we will look at ways to leverage those in the HDF platform and through our add-on solutions to drive value through data," said Weatherston.

"Successfully raising $30 million in such a challenging capital markets environment is a testament to the strength and desirability of Smile's technological offering and the broad appeal of the vision of its founders," commented Smile Digital Health Chairman, George Rizk.

In 2022, Smile was cited by The Globe and Mail's ranking of Canada's Top Growing Companies. It was also recognized as a 2022 Deloitte Technology Fast 50™ and North America Technology Fast 500™ company for the second year running.

"Smile is a leader in the Health Data Fabric space and is a highly innovative and client-focused company looking to improve healthcare through access to digital information. Its work with Astrata, a company created by UPMC Enterprises, demonstrates Smile's ability to deliver value to many parties in the health ecosystem," said Brent Burns, Executive Vice President at UPMC Enterprises, the venture capital and commercialization arm of leading health system UPMC. "UPMC shares the same passion as Smile for improving healthcare via innovation."

Smile Digital Health has grown rapidly from a 2016 start-up to being a recognized leader in the digital health solutions space, servicing clients across the healthcare spectrum, including many top tier payers and providers across the United States and 18 other countries, as well as research institutions, other health information technology companies and government agencies. 

Smile's legal advisors in conjunction with this financing were Davies Ward Phillips & Vineberg LLP.

###

About Smile Digital Health

Smile Digital Health is a health information technology company focused on delivering better global health through open standards. Our enterprise-grade, open framework data fabric and integration platform fuels healthcare's digital transformation and accelerates value creation across all patient journeys at scale. Powered by our HL7® FHIR® standard-based clinical data repository (#SmileInside), our platform enables collaboration and allows organizations to ingest, transform, store, enrich, analyze, aggregate and meaningfully share the health information to power digital transformation. We prepare healthcare providers, payers, researchers and life sciences organizations for a connected future beyond legacy systems, adding new value through intelligent use of information and ultimately delivering better patient outcomes. For more information, visit: SmileDigitalHealth.com. 

sam\u00aex1
sam\u00aex1

LAS VEGAS, January 26, 2023 (Newswire.com) - ZetrOZ Systems will demonstrate the effectiveness of its sam®x1 and sam®2.0 sustained acoustic medicine devices for soft tissue injury therapies at the Las Vegas Regenerative Medicine and MSK Ultrasound Course, the longest-running medical education seminar of its kind, from Jan. 26 to 28 in Las Vegas.

The sam®x1 is the first FDA-cleared pain management device of its kind cleared for everyday, at-home use, and the sam®2.0 is the long-duration solution. Both are wearable pain relief ultrasound devices that inhibit inflammation and accelerate natural healing by stimulating tissue regeneration, increasing circulation, and nutrient exchange in deep musculoskeletal tissue.

The multiple-day educational course, at the Planet Hollywood Resort and Casino, Las Vegas, welcomes hundreds of practitioners as varied as orthopedic surgeons, sports medicine physicians, PM&R physicians, pain management physicians, interventional radiologists, rheumatologists, physical therapists, naturopathic doctors, chiropractors, podiatrists, physician assistants, nurse practitioners, diagnostic sonographers and more.

"The Las Vegas Regenerative Medicine and MSK Ultrasound Course brings in leading physicians and other practitioners who will speak on the administration of ultrasound technology and its many benefits - it offers patients options beyond pain medication or surgery," says Dr. George Lewis, founder and CEO of ZetrOZ Systems. "We're incredibly excited to attend and bring awareness of our innovative pain relief ultrasound device portfolio to more healthcare professionals."

The first day of the program will be dedicated to reviewing scientific updates, new regulations, and best practices of the orthopedic discipline. The last two days will focus on practical ultrasound operation, and ZetrOZ Systems sam®x1 and sam®2.0 will be joining the lineup of medical treatment options available for clinicians to review and apply.

Backed by more than 30 clinical studies, sam® technology was developed with research funded by the National Institutes of Health and the U.S. Department of Defense with the intent of finding new methods of soft tissue healing that reduce the use of narcotics and invasive treatments.

To learn more about sustained acoustic medicine and its effectiveness in soft tissue healing, visit zetroz.com.

About ZetrOZ Systems

ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of +46 patents. The exclusive manufacturer and developer of the sam® product line is designed for the treatment of acute and chronic musculoskeletal conditions.

Academic Urology Research Investigators Consortium
AURIC Logo

SARATOGA SPRINGS, N.Y., January 26, 2023 (Newswire.com) - Criterium, Inc., a full-service Contract Research Organization (CRO), is pleased to announce AURIC (Academic Urology Research Investigators Consortium) — a newly formed GU Oncology Consortium. The newest oncology consortia created by Criterium, Inc., it was launched in late July to support advanced oncology clinical research initiatives in translational research for genito-urinary (GU) cancers. This is the 5th specialty oncology consortia managed by Criterium. AURIC will follow in the footsteps of Criterium's other successful Consortia: in GI, Academic GI Cancer Consortium (AGICC); in breast, Academic Breast Cancer Consortium (ABRCC); in thoracic/lung cancers, Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC); and in multiple myeloma, Academic Myeloma Cancer Consortium (AMyC). These consortia are currently comprised of 41 renowned institutions and 73 Key Opinion Leaders in North America.

Directing the new consortium will be Dr. Thomas Flaig, Vice Chancellor of Research for the University of Colorado in Denver at the Anschutz Medical Campus. Dr. Flaig brings his significant clinical and translational research experience to this leadership position, having led both local and national multi-center clinical trials and served as the local principal investigator on a large number of Phase I, II and III studies. He previously served as medical director of the clinical trials office and associate director of clinical research at the CU Cancer Center. Known nationally for his work on bladder cancer, Dr. Flaig has been a member of the National Cancer Institute's Investigational Drug Steering Committee and the bladder cancer task force. He also serves as chair of the bladder cancer committee for the National Comprehensive Care Network. He is excited about the prospect of completing unique and forward-thinking trials from pharmaceutical companies investigating GU indications. His expertise and unique vision for research in the GU indications will create new possibilities for GU therapies and clinical studies that demonstrate important value for pharmaceutical sponsors and the patients who participate in these important trials.

About Criterium Inc.
Criterium is a full-service, global and technology-driven contract research organization that offers a unique mix of high-quality, innovative clinical research solutions for the biopharmaceutical, pharmaceutical, medical device and CRO industries. Visit us online: https://www.criteriuminc.com/  

About the Oncology Consortia of Criterium (OCC)
The Oncology Consortia of Criterium are a collaboration of outstanding Cancer Research Consortia delivering innovative research and unparalleled expertise. The Consortia Model utilizes translational science methodologies to streamline cancer research and development. Each member is usually located at a hospital or research center associated with an academic institution that has superior infrastructure and staff to meet the requirements — not only for translational and investigator-initiated studies, but also design and completion of all phases of clinical trials. Our model allows us to provide expertise and innovative solutions for the rapid design, implementation, and management of complex cancer trials. Visit the Consortia: https://www.criteriuminc.com/oncology-consortia/

SpendMend
SpendMend

GRAND RAPIDS, Mich., January 26, 2023 (Newswire.com) - SpendMend, a leading provider of cost-saving solutions for the healthcare industry, today announced record earnings in 2022, marking their fourth consecutive year of over 30% revenue growth. The company saw a 20% increase in employee count and a healthy increase in clients to over 150 major U.S. health systems, comprising over 3,000 hospitals and facilities. Clients also shared in the good news, enjoying a 32% increase in hard dollar savings delivered to their bottom line as compared to the previous year.

In addition to the strong growth indicators, SpendMend completed several major deals throughout the calendar year of 2022. The company secured a controlling investment from Morgan Stanley Capital Partners ("MSCP"), joined by additional investments from Corewell/Spectrum Health Ventures and Memorial Hermann Health System. 

"For several years, SpendMend has been establishing a new critical segment for the healthcare industry, the Cost-Cycle," states Steve Rodgers, Managing Director and Head of Healthcare at MSCP. "In 2022, we saw accelerated adoption in this growing segment; hospitals and health systems are using SpendMend's emerging cost-cycle platform as an effective strategy to drive significant bottom-line revenue and cost-savings while managing through pricing pressure, supply chain delays, and other lingering effects of the pandemic."

SpendMend, in the past year, expanded its cost-cycle platform through the acquisition of three leading healthcare providers including: VIE Healthcare Consulting, a leading cost consultant for hospitals; Trulla, a next-generation pharmacy procurement platform; and finally, the healthcare division of Moody Associates, P.A., a provider of profit recovery and contract-compliance services. 

Through their innovative suite of cost-cycle solutions, SpendMend helped U.S. healthcare networks to illuminate the "dark data" in their cost-cycle, unlocking trapped dollars and improving operations and overall efficiency. 

"Controlling costs is arguably the biggest challenge facing health systems across the country today," said Scott McLean, Managing Director at Corewell/Spectrum Health Ventures. "Simply put, SpendMend's suite of cost-cycle solutions helps hospitals reduce costs and optimize future savings. SpendMend is a perfect fit for the Corewell/Spectrum portfolio, and they are fast becoming an indispensable partner for U.S. Health Systems."

"For years, we have been guided by a mission to positively impact patient care by delivering value to our clients through our innovative cost-saving solutions," states SpendMend founder and CEO, Dan Geelhoed. "Through that lens, I believe our biggest success from the past year was watching our clients invest the bottom-line benefits of our work back into their patient communities."

About SpendMend 

SpendMend is the leading provider of tech-enabled, cost-savings solutions in the healthcare industry. By combining data, proprietary technology, and analytics with healthcare expertise, SpendMend partners with healthcare networks to expose and improve hidden costs in meaningful ways. The company's mission is to help its clients improve patient care through innovative cost-saving solutions.